Frontiers in Oncology最新文献

{"title":"Gut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.","authors":"Zhengshi Wang, Haotian Chen, Yongqiang Liu, Libin Zou, Zhijin Zhang, Zhiqiang Yin, Shiyu Mao, Changcheng Guo, Bin Yang, Pengfei Wu, Xudong Yao","doi":"10.3389/fonc.2024.1466190","DOIUrl":"https://doi.org/10.3389/fonc.2024.1466190","url":null,"abstract":"<p><strong>Purpose: </strong>Studies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.</p><p><strong>Patients and methods: </strong>Genome-wide association study (GWAS) summary datasets were collected from the public databases. There were 418 bacterial traits, 452 metabolites, 91 cytokines, 5408 cases of prostate cancer from East Asia, and 109,347 controls included. Mendelian randomization (MR) analyses were performed to investigate their causal relationships. Sensitivity analyses were conducted to test the reliability of MR results. Furthermore, the FinnGen database was used to assess the generalizability of our findings based on Asians.</p><p><strong>Results: </strong>There were a total of 17 bacterial traits, 28 metabolites (including 2 microbiota-associated metabolites), and 9 cytokines to be significantly associated with prostate cancer in Asians (P < 0.05). Further MR analyses of these positive results indicated that <i>G_Ruminococcaceae UCG014</i>/TNFSF10 axis, <i>G_Anaerofilum</i>/TNFRSF14 axis, <i>G_Erysipelotrichaceae UCG003</i>/TNFSF10 axis, and P_Proteobacteria/cholesterol axis were key signaling pathways involved in the progression of prostate cancer. Notably, <i>G_Ruminococcaceae UCG014</i>/TNFSF10 axis and <i>G_Anaerofilum</i>/TNFRSF14 axis were found to act as protective factors, while the other two signaling axes played a crucial role in promoting the progression of prostate cancer. Sensitivity analyses further confirmed the reliability of our findings. Using the European population as outcome, we further assessed the generalizability of our conclusions and found limited applicability to Europeans.</p><p><strong>Conclusions: </strong>We found that there were causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in Asians. The causal effects of gut microbiota on prostate cancer were partially mediated by metabolites and cytokines. These findings might contribute to the development of new therapeutic strategies for prostate cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1466190"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis.","authors":"Hongkun Xu, Tingting Lu, Yajie Liu, Jingqi Yang, Simeng Ren, Baojin Han, Honghao Lai, Long Ge, Jie Liu","doi":"10.3389/fonc.2024.1506366","DOIUrl":"https://doi.org/10.3389/fonc.2024.1506366","url":null,"abstract":"<p><strong>Objective: </strong>The prevalence of long COVID among cancer patients remains unknown. This study aimed to determine the prevalence of long COVID and explore potential risk factors among cancer patients.</p><p><strong>Methods: </strong>A systematic search was performed on PubMed, Web of Science, and Embase from database inception until 21 March 2024, to identify studies that reported long COVID in cancer patients. Two investigators independently screened the studies and extracted all information about long COVID in cancer patients for subsequent analysis. Methodological quality was assessed using the \"Joannagen Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data\".</p><p><strong>Results: </strong>A total of 13 studies involving 6,653 patients were included. The pooled prevalence of long COVID was 23.52% [95% confidence interval (CI), 12.14% to 40.64%] among cancer patients reported experiencing long COVID after acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled prevalence of any long COVID in cancer patients was 20.51% (95% CI, 15.91% to 26.03%), 15.79% (95% CI, 11.39% to 21.47%), and 12.54% (95% CI, 6.38% to 23.18%) in 3, 6, and 12 months follow-up duration. Fatigue was the most common symptom, followed by respiratory symptoms, myalgia, and sleep disturbance. Patients with comorbidities had a significantly higher risk of experiencing long COVID [odds ratio (OR) = 1.72; 95% CI, 1.09 to 2.70; <i>p</i> = 0.019]. No statistically significant differences in sex, primary tumor, or tumor stage were detected.</p><p><strong>Conclusion: </strong>Nearly a quarter of cancer patients will experience long COVID after surviving from SARS-CoV-2 infection, and this would even last for 1 year or longer. Fatigue, respiratory symptoms, myalgia, and sleep disturbance need to be more addressed and managed to reduce symptom burden on cancer patients and improve quality of life. Patients with comorbidities are at a high risk of developing long COVID. Further randomized controlled trials with rigorous methodological designs and large sample sizes are needed for future validation.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023456665.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1506366"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling hotspots of emerging research in the miRNA-related mechanism underlying cancer through comprehensive bibliometric analysis with implications for precision medicine and non-invasive diagnostics.","authors":"Zhirui Zhang, Wenhuan Song, Wenyu Chen, Wenze Cui, Wenyi Chen, Qinheng Zhang, Wenwen Ji, Yinglin Wang, Jiayi Wang, Wenhao Yu, Mingkun Yu, Tao Hao, Hong Jiang","doi":"10.3389/fonc.2024.1521251","DOIUrl":"https://doi.org/10.3389/fonc.2024.1521251","url":null,"abstract":"<p><strong>Background and objective: </strong>MicroRNAs (miRNAs) are implicated in cancer by exerting roles in tumor growth, metastasis, and even drug resistance. The general trends of miRNA research in diverse cancers are not fully understood. In this work, miRNA-related research in colorectal cancer, prostate cancer, leukemia, and brain tumors was analyzed in search of key research trends with clinical potential.</p><p><strong>Methods: </strong>A bibliometric analysis of articles, spanning from 2014 to 2024, was carried out with the major focus laid on four types of cancers. The Co-citation network analysis, keyword bursts, and the collaborative pattern were done in VOSviewer and CiteSpace, respectively.</p><p><strong>Results: </strong>Colorectal cancer had the highest publication volume, with research primarily focusing on gene expression, extracellular vesicles, and non-coding RNAs. Prostate cancer showed a shift toward clinical applications, while leukemia and brain tumor research, though less extensive, highlighted miRNA's potential in early diagnosis and treatment. Co-citation analysis identified emerging research collaborations and key contributors.</p><p><strong>Conclusion: </strong>miRNA plays a pivotal role in cancer diagnosis, biomarker development, and therapeutic interventions. With advancements in non-invasive diagnostics and personalized medicine, miRNA offers significant potential for clinical applications. Future research should focus on miRNA's role in drug resistance and combination therapies to accelerate its clinical translation.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1521251"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Selpercatinib in the treatment of <i>RET</i> fusion-positive advanced lung adenocarcinoma: a challenging clinical case.","authors":"Raffaella Pagliaro, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Susan F M Campbell, Fabio Perrotta, Andrea Bianco","doi":"10.3389/fonc.2024.1500449","DOIUrl":"https://doi.org/10.3389/fonc.2024.1500449","url":null,"abstract":"<p><strong>Background: </strong>Rearranged during transfection (<i>RET</i>) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective <i>RET</i> inhibitor, has demonstrated efficacy in various solid tumors harboring <i>RET</i> alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a <i>RET</i> fusion.</p><p><strong>Case presentation: </strong>A 59-year-old woman with a history of stage IV lung adenocarcinoma harboring a <i>KIF5B-RET</i> fusion presented with disease progression following first-line chemo-immunotherapy. Selpercatinib was initiated as a targeted therapy, leading to a notable radiographic response and clinical improvement. The patient experienced a significant reduction in tumor burden and reported improved symptom control, with no significant adverse effects during the 21-month follow-up period.</p><p><strong>Conclusions: </strong>This case highlights the efficacy and tolerability of selpercatinib in treating advanced lung adenocarcinoma with a <i>RET</i> fusion. The observed clinical response supports the early use of selpercatinib as a targeted therapy for <i>RET</i> fusion-positive NSCLC, including in patients with compromised general and respiratory conditions, especially in cases refractory to conventional treatments. Long-term follow-up studies are warranted to validate these findings and assess the durability of responses.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1500449"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy.","authors":"David J Benjamin, Robert C Hsu","doi":"10.3389/fonc.2024.1457006","DOIUrl":"https://doi.org/10.3389/fonc.2024.1457006","url":null,"abstract":"<p><p>Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or metastatic disease. With the emergence of immune checkpoint inhibitors and targeted therapies for specific genomic aberrations in the treatment of over a dozen other cancers, recent studies have sought to identify therapies other than chemotherapy in treating this uncommon cancer. Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1457006"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-based intratumoral and peritumoral radiomics for assessing deep myometrial invasion in patients with early-stage endometrioid adenocarcinoma.","authors":"Jing Yang, Yang Liu, Xiaolong Liu, Yaoxin Wang, Xianhong Wang, Conghui Ai, Qiu Bi, Ying Zhao","doi":"10.3389/fonc.2024.1474427","DOIUrl":"https://doi.org/10.3389/fonc.2024.1474427","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effectiveness of magnetic resonance imaging (MRI)-based intratumoral and peritumoral radiomics models for predicting deep myometrial invasion (DMI) of early-stage endometrioid adenocarcinoma (EAC).</p><p><strong>Methods: </strong>The data of 459 EAC patients from three centers were retrospectively collected. Radiomics features were extracted separately from the intratumoral and peritumoral regions expanded by 0 mm, 5 mm, and 10 mm on unimodal and multimodal MRI. Then, various radiomics models were developed and validated, and the optimal model was confirmed. Integrated models were constructed by ensemble and stacking algorithms based on the above radiomics models. The models' performance was evaluated using the area under the curve (AUC).</p><p><strong>Results: </strong>The multimodal MRI-based radiomics model, which included both intratumoral and peritumoral regions expanded by 5 mm, was the optimal radiomics model, with an AUC of 0.74 in the validation group. When the same integrated algorithm was utilized, the integrated models with 5-mm expansion presented higher AUCs than those with 0-mm and 10-mm expansion in the validation group. The performance of the stacking model and ensemble model with 5-mm expansion was similar, and their AUCs were 0.74 and 0.75, respectively.</p><p><strong>Conclusion: </strong>The multimodal radiomics model from the intratumoral and peritumoral regions expanded by 5 mm has the potential to improve the performance for detecting DMI of early-stage EAC. The integrated models are of little value in increasing the prediction.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1474427"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report.","authors":"Shuangying Zhao, Xiaodong Zhang, Jialiang Luo, Huanjun Yan, Jianlei Zhang, Rongfeng Lin, Kelei Zhu","doi":"10.3389/fonc.2024.1476593","DOIUrl":"https://doi.org/10.3389/fonc.2024.1476593","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conversion protocol of immuno-chemotherapy has been applied for advanced liver cancer. However, little has been reported about iCCA conversion therapy. The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 cycles of conversion therapy, enhanced CT showed that the patient's tumor had shrunk to nearly half its original size, making radical resection possible. Postoperative pathology showed a complete pathological response. This provides a new way to convert advanced iCCA into resectable state.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1476593"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus.","authors":"Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Sayyed Hammad, Dina Hamza, Hassan Jaafar, Hussam Marashi","doi":"10.3389/fonc.2024.1443962","DOIUrl":"https://doi.org/10.3389/fonc.2024.1443962","url":null,"abstract":"<p><p>Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of \"HER2-low\" expression as a targetable category has caused a paradigm shift in the management of breast cancer. Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd), an ADC, has now also been approved to treat metastatic or unresectable HER2-low breast cancers. Despite the inherent specificity of an ADC, the risk of off-site toxicity exists and is an essential component while assessing the risk-benefit ratio of the treatment. Developing strategies to balance efficacy and safety is crucial, especially for newly approved therapies like T-DXd. Regional perspectives, cultural beliefs, and demographic factors influence treatment decisions and outcomes. The objective of this paper is to establish a UAE-specific consensus among oncologists on practical T-DXd treatment considerations and management of associated side effects. Establishing a consensus on monitoring and managing T-DXd side effects among experts can promote informed decision-making.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1443962"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count.","authors":"Rocío Del Campo-Pedrosa, Alfonso Martín-Carnicero, Ana González-Marcos, Alfredo Martínez","doi":"10.3389/fonc.2024.1540165","DOIUrl":"https://doi.org/10.3389/fonc.2024.1540165","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2024.1411096.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1540165"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different surgical methods of hysterectomy for the management of endometrial cancer: a systematic review and network meta-analysis.","authors":"Yuquan Yuan, Qin Tan, Yingfan Chen, Keyang Zhu, Bin Pan, Bao Liu, Chunyan Ren, Ganghui Li, Cheng Chen, Chengzhi Zhao","doi":"10.3389/fonc.2024.1524991","DOIUrl":"https://doi.org/10.3389/fonc.2024.1524991","url":null,"abstract":"<p><strong>Background: </strong>Emerging surgical methods are utilized to treat endometrial cancer. The study aimed to assess the efficacy and safety of four common surgical methods of hysterectomy.</p><p><strong>Methods: </strong>We systematically searched the PubMed, Cochrane Library databases, Medline, EMBASE and Web of Science from their inception until April 30, 2024. We used hazard ratios (HR) for overall survival (OS) and disease-free (DFS), odds ratios (OR) for categorical outcomes, and mean differences (MD) for continuous outcomes with 95% confidence intervals. These were pooled in Bayesian network meta-analysis models. The surface under the cumulative ranking curve (SUCRA) was used to illuminate the probability that each method would be the best for each outcome.</p><p><strong>Results: </strong>Thirty studies comprising 13446 patients were included. Robotic hysterectomy (RH) retrieved fewer pelvic lymph nodes than open hysterectomy (OH). OH showed a significantly higher postoperative complication rate than laparoscopic hysterectomy (LH) and RH. LH had a higher intraoperative complication rate than OH. According to SUCRA values, OH ranked the highest in the number of retrieved pelvic lymph nodes (0.89), intraoperative complications (0.73), and operative time (0.97). LH ranked the highest in DFS (0.81) and overall survival (OS) (0.87). RH ranked the highest in the postoperative complications (0.95). Laparoscopic-assisted vaginal hysterectomy (LAVH) ranked the highest in number of retrieved para-aortic lymph nodes (0.72).</p><p><strong>Conclusions: </strong>There are no significant differences among the four surgical methods in DFS or OS. The use of uterine manipulators does not affect prognosis. OH is the best method for shortening operative time, dissecting the pelvic lymph nodes and controlling intraoperative complications. LH and LAVH have an advantage in para-aortic lymph node dissection. Besides, LH has the best advantage in DFS and OS. RH has advantages in controlling surgical complications.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024529974.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1524991"},"PeriodicalIF":3.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}